Meropenem Kalceks (Meropenem)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This leads to weakened cell walls, osmotic instability and bacterial cell lysis, providing broad‑spectrum activity against many resistant organisms.

The exact dosage of Meropenem Kalceks is determined by the prescribing clinician based on the type and severity of infection, the patient’s renal function, body weight and other clinical factors. No fixed regimen is provided here.

Meropenem is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies the potential risk, and caution is advised while breastfeeding.

To place an order, submit an enquiry on the Meropenem Kalceks product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Meropenem belongs to the carbapenem class, offering broader Gram‑negative coverage and greater stability against β‑lactamases than most penicillins or cephalosporins. Compared with other carbapenems such as imipenem, meropenem has a lower risk of seizures and does not require co‑administration of a renal protective agent.

Meropenem Kalceks should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the solution before use.

The medication is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional, typically over a period of 15‑30 minutes, with the exact infusion rate and duration set by the treating physician.

Serious adverse events include seizures (particularly in patients with renal impairment or high doses), severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and Clostridioides difficile‑associated colitis, which can cause life‑threatening diarrhea.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation should avoid this drug. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting medications listed under major interactions.